Product Description
BR55, an ultrasound contrast agent functionalized with a heterodimer peptide targeting the vascular endothelial growth factor receptor 2 (VEGFR2), was evaluated in vitro and in vivo, demonstrating its potential for specific tumor detection.
Mechanisms of Action: Imaging Agent,VEGFR2
Novel Mechanism: Yes
Modality: Diagnostic Agent
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bracco Imaging
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Breast Diseases|Inflammatory Breast Cancer|Ovarian Cancer|Ovarian Diseases|Thyroid Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20220634 | P2 |
Not yet recruiting |
Breast Diseases|Inflammatory Breast Cancer|Ovarian Cancer|Thyroid Cancer|Ovarian Diseases |
None |